US Stock Market Move | The Q3 financial report exceeded expectations comprehensively but still failed to satisfy the market's "appetite." Applied Materials (AMAT.US) saw a nearly 6% drop in early trading.
On Friday, Applied Materials (AMAT.US) fell nearly 6% in early trading, currently reported at $503.94.
On Friday, Applied Materials (AMAT.US) fell nearly 6% in the morning session, now reported at $503.94. In terms of news, Applied Materials delivered strong third-quarter results and provided guidance for the fourth quarter that exceeded market expectations. However, given the significant rise in stock price this year and the high expectations for AI capital expenditures already present in the market, this "better-than-expected" earnings report did not receive market recognition.
For the third fiscal quarter, Applied Materials reported revenue of $9.115 billion, surpassing the expected $9 billion, reflecting a year-over-year increase of 25% and hitting a record high; GAAP net income was $2.538 billion, a 43% year-over-year increase, with adjusted earnings per share of $3.50, exceeding the expected $3.42 and up 41%, also setting a record. The company expects fourth-quarter revenue to be approximately $10.25 billion, about 7% higher than the average analyst expectation. Adjusted earnings per share are projected to be $4.02, well above the market expectation of $3.72.
Related Articles

How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.
How to choose AI applications in Hong Kong stocks? DIAGENS-B (02526): A rare vertical AI target with high growth and strong barriers.

Valuation at $2 trillion! Anthropic may become the largest IPO in history, starting its roadshow in October and going public before the mid-term elections in November.

Astrazeneca PLC Sponsored ADR (AZN.US) has received accelerated approval from the FDA for a new breast cancer drug, and Wall Street estimates that sales could reach $2.3 billion by 2032.

RECOMMEND





